Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 9
Submit an article Journal homepage
489
Views
62
CrossRef citations to date
0
Altmetric
Review

Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer

Marianne M Stanford University of Western Ontario, Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, London, Ontario, N6G 2V4, Canada
&
Grant McFadden University of Florida, Depertment of Molecular Genetics and Microbiology, Gainesville, FL 32610, USA [email protected]
Pages 1415-1425 | Published online: 29 Aug 2007

Bibliography

  • DOCK G: Influence of complicating diseases upon leukemia. Am. J. Med. Sci. (1904) 127:563-592.
  • KELLY E, RUSSELL SJ: History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. (2007) 15(4):651-659.
  • LIU TC, GALANIS E, KIRN D: Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. (2007) 4(2):101-117.
  • VAHA-KOSKELA MJ, HEIKKILA JE, HINKKANEN AE: Oncolytic viruses in cancer therapy. Cancer Lett. (2007).
  • WOO CY, OSADA T, CLAY TM, LYERLY HK, MORSE MA: Recent clinical progress in virus-based therapies for cancer. Expert Opin. Biol. Ther. (2006) 6(11):1123-1134.
  • WOO Y, ADUSUMILLI PS, FONG Y: Advances in oncolytic viral therapy. Curr. Opin. Investig. Drugs (2006) 7(6):549-559.
  • CHERNAJOVSKY Y, LAYWARD L, LEMOINE N: Fighting cancer with oncolytic viruses. BMJ (2006) 332(7534):170-172.
  • THORNE SH, BARTLETT DL, KIRN DH: The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. (2005) 5(4):429-443.
  • STANFORD MM, MCFADDEN G, KARUPIAH G, CHAUDHRI G: Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. (2007) 85(2):93-102.
  • RAHAUS M, DESLOGES N, WOLFF MH: Varicella-zoster virus requires a functional PI3K/Akt/GSK-3α/β signaling cascade for efficient replication. Cell Signal. (2007) 19(2):312-320.
  • ENJUANES L, ALMAZAN F, SOLA I, ZUNIGA S: Biochemical aspects of coronavirus replication and virus-host interaction. Annu. Rev. Microbiol. (2006) 60:211-230.
  • SALSMAN J, TOP D, BOUTILIER J, DUNCAN R: Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J. Virol. (2005) 79(13):8090-8100.
  • KAZEMI S, PAPADOPOULOU S, LI S et al.: Control of α subunit of eukaryotic translation initiation factor 2 (eIF2 α) phosphorylation by the human papillomavirus type 18 E6 oncoprotein: implications for eIF2 α-dependent gene expression and cell death. Mol. Cell Biol. (2004) 24(8):3415-3429.
  • CASTEDO M, ROUMIER T, BLANCO J et al.: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J. (2002) 21(15):4070-4080.
  • NICHOLSON KM, ANDERSON NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. (2002) 14(5):381-395.
  • SCHMELZLE T, HALL MN: TOR, a central controller of cell growth. Cell (2000) 103(2):253-262.
  • BELL JC: Oncolytic viruses: what's next? Curr. Cancer Drug Targets (2007) 7(2):127-131.
  • KASUYA H, TAKEDA S, SHIMOYAMA S et al.: Oncolytic virus therapy – foreword. Curr. Cancer Drug Targets (2007) 7(2):123-125.
  • ROBERTS MS, LORENCE RM, GROENE WS, BAMAT MK: Naturally oncolytic viruses. Curr. Opin. Mol. Ther. (2006) 8(4):314-321.
  • KIRN D: Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene (2000) 19(56):6660-6669.
  • HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. (1997) 3(6):639-645.
  • ROGULSKI KR, FREYTAG SO, ZHANG K et al.: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. (2000) 60(5):1193-1196.
  • RIES SJ: Elucidation of the molecular mechanism underlying tumor-selective replication of the oncolytic adenovirus mutant ONYX-015. Future Oncol. (2005) 1(6):763-766.
  • O'SHEA CC, JOHNSON L, BAGUS B et al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 6(6):611-623.
  • HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9(2):555-561.
  • MAKOWER D, ROZENBLIT A, KAUFMAN H et al.: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. (2003) 9(2):693-702.
  • MULVIHILL S, WARREN R, VENOOK A et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. (2001) 8(4):308-315.
  • NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. (2001) 8(10):746-759.
  • GARBER K: China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. (2006) 98(5):298-300.
  • LIU TC, KIRN D: Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. (2007) 67(2):429-432.
  • FIGOVA K, HRABETA J, ECKSCHLAGER T: Reovirus – possible therapy of cancer. Neoplasma (2006) 53(6):457-462.
  • AGHI M, MARTUZA RL: Oncolytic viral therapies – the clinical experience. Oncogene (2005) 24(52):7802-7816.
  • BELL JC, LICHTY B, STOJDL D: Getting oncolytic virus therapies off the ground. Cancer Cell (2003) 4(1):7-11.
  • THORNE SH, HWANG TH, KIRN DH: Vaccinia virus and oncolytic virotherapy of cancer. Curr. Opin. Mol. Ther. (2005) 7(4):359-365.
  • SHEN Y, NEMUNAITIS J: Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther. (2005) 11(2):180-195.
  • WHITMAN ED, TSUNG K, PAXSON J, NORTON JA: In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery (1994) 116(2):183-188.
  • MCCART JA, WARD JM, LEE J et al.: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. (2001) 61(24):8751-8757.
  • PUHLMANN M, BROWN CK, GNANT M et al.: Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. (2000) 7(1):66-73.
  • MOSS B, CARROLL MW, WYATT LS et al.: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. (1996) 397:7-13.
  • ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9(12):1001-1012.
  • BULLER RM, CHAKRABARTI S, COOPER JA, TWARDZIK DR, MOSS B: Deletion of the vaccinia virus growth factor gene reduces virus virulence. J. Virol. (1988) 62(3):866-874.
  • BULLER RM, CHAKRABARTI S, MOSS B, FREDRICKSON T: Cell proliferative response to vaccinia virus is mediated by VGF. Virology (1988) 164(1):182-192.
  • GUO ZS, BARTLETT DL: Vaccinia as a vector for gene delivery. Expert Opin. Biol. Ther. (2004) 4(6):901-917.
  • GUO ZS, NAIK A, O'MALLEY ME et al.: The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. (2005) 65(21):9991-9998.
  • YANG S, GUO ZS, O'MALLEY ME et al.: A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus. Gene Ther. (2007) 14(8):638-647.
  • MASTRANGELO MJ, LATTIME EC: Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. (2002) 9(12):1013-1021.
  • MASTRANGELO MJ, MAGUIRE HC, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Exp. Med. Biol. (2000) 465:391-400.
  • MASTRANGELO MJ, MAGUIRE HC Jr, EISENLOHR LC et al.: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. (1999) 6(5):409-422.
  • KIM JH, OH JY, PARK BH et al.: Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. (2006) 14(3):361-370.
  • HU Y, LEE J, MCCART JA et al.: Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J. Virol. (2001) 75(21):10300-10308.
  • TAGAWA M, KAWAMURA K, SHIMOZATO O et al.: Virology- and immunology-based gene therapy for cancer. Cancer Immunol. Immunother. (2006) 55(11):1420-1425.
  • BEUKEMA EL, BROWN MP, HAYBALL JD: The potential role of fowlpox virus in rational vaccine design. Expert Rev. Vaccines (2006) 5(4):565-577.
  • PETRULIO CA, KAUFMAN HL: Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines (2006) 5(1):9-19.
  • ARLEN PM, GULLEY JL: Therapeutic vaccines for prostate cancer: a review of clinical data. Curr. Opin. Investig. Drugs (2005) 6(6):592-596.
  • SKINNER MA, LAIDLAW SM, ELDAGHAYES I, KAISER P, COTTINGHAM MG: Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines (2005) 4(1):63-76.
  • HWANG C, SANDA MG: Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Curr. Opin. Mol. Ther. (1999) 1(4):471-479.
  • TARTAGLIA J, PINCUS S, PAOLETTI E: Poxvirus-based vectors as vaccine candidates. Crit. Rev. Immunol. (1990) 10(1):13-30.
  • FENNER F, RATCLIFFE FN: Myxomatosis. Cambridge University Press, Cambridge, UK (1965).
  • FENNER F: Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev. (2000) 24(2):123-133.
  • STANFORD MM, WERDEN SJ, MCFADDEN G: Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet. Res. (2007) 38(2):299-318.
  • ZUNIGA MC: A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation. Virus Res. (2002) 88(1-2):17-33.
  • KERR P, MCFADDEN G: Immune responses to myxoma virus. Viral Immunol. (2002) 15(2):229-246.
  • BARRETT JW, CAO JX, HOTA-MITCHELL S, MCFADDEN G: Immunomodulatory proteins of myxoma virus. Semin. Immunol. (2001) 13(1):73-84.
  • ANDREWES CH, HARISIJADES S: Propagation of myxoma virus in one-day old mice. Br. J. Exp. Pathol. (1955) 36(1):18-21.
  • MCCABE VJ, TARPEY I, SPIBEY N: Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine (2002) 20(19-20):2454-2462.
  • MCFADDEN G: Poxvirus tropism. Nat. Rev. Microbiol. (2005) 3(3):201-213.
  • WANG F, MA Y, BARRETT JW et al.: Disruption of Erk-dependent type I IFN induction breaks the myxoma virus species barrier. Nat. Immunol. (2004) 5(12):1266-1274.
  • SYPULA J, WANG F, MA Y, BELL JC, MCFADDEN G: Myxoma virus tropism in human tumor cells. Gene Ther. Mol. Biol. (2004) 8:108-114.
  • LUN X, YANG W, ALAIN T et al.: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. (2005) 65(21):9982-9990.
  • MOSSMAN K, LEE SF, BARRY M, BOSHKOV L, MCFADDEN G: Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J. Virol. (1996) 70(7):4394-4410.
  • JOHNSTON JB, WANG G, BARRETT JW et al.: Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J. Virol. (2005) 79(16):10750-10763.
  • WANG G, BARRETT JW, STANFORD M et al.: Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA (2006) 103(12):4640-4645.
  • HAAS-KOGAN D, SHALEV N, WONG M et al.: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. (1998) 8(21):1195-1198.
  • DAHIA PL, AGUIAR RC, ALBERTA J et al.: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum. Mol. Genet. (1999) 8(2):185-193.
  • AMORNPHIMOLTHAM P, SRIURANPONG V, PATEL V et al.: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. (2004) 10(12 Part 1):4029-4037.
  • CHEN YL, LAW PY, LOH HH: Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr. Med. Chem. Anticancer Agents (2005) 5(6):575-589.
  • CHOW LM, BAKER SJ: PTEN function in normal and neoplastic growth. Cancer Lett. (2006).
  • PEDRERO JM, CARRACEDO DG, PINTO CM et al.: Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer (2005) 114(2):242-248.
  • HYUN T, YAM A, PECE S et al.: Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood (2000) 96(10):3560-3568.
  • STILES B, GILMAN V, KHANZENZON N et al.: Essential role of AKT-1/protein kinase Ba in PTEN-controlled tumorigenesis. Mol. Cell Biol. (2002) 22(11):3842-3851.
  • GEORGAKIS GV, YOUNES A: From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev. Anticancer Ther. (2006) 6(1):131-140.
  • STANFORD MM, BARRETT JW, NAZARIAN SH, WERDEN S, MCFADDEN G: Oncolytic virotherapy synergism with signaling inhibitors: rapamycin increases myxoma virus tropism for human tumor cells. J. Virol. (2007) 81(3):1251-1260.
  • DUNN C, CROOM KF: Everolimus: a review of its use in renal and cardiac transplantation. Drugs (2006) 66(4):547-570.
  • MARTY FM, BRYAR J, BROWNE SK et al.: Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood (2007) 110(2):490-500.
  • WEBSTER AC, LEE VW, CHAPMAN JR, CRAIG JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation (2006) 81(9):1234-1248.
  • JOHNSTON JB, MCFADDEN G: Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol. (2004) 6(8):695-705.
  • BARRETT JW, SHUN CHANG C, WANG G et al.: Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology (2006).
  • BEDARD EL, JIANG J, ARP J et al.: Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation (2006) 81(6):908-914.
  • LUCAS A, MCFADDEN G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J. Immunol. (2004) 173(8):4765-4774.
  • DAI E, GUAN H, LIU L et al.: Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J. Biol. Chem. (2003) 278(20):18563-18572.
  • NASH P, LUCAS A, MCFADDEN G: SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. Adv. Exp. Med. Biol. (1997) 425:195-205.
  • MOSSMAN K, NATION P, MACEN J et al.: Myxoma virus M-T7, a secreted homolog of the IFN-γ receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology (1996) 215(1):17-30.
  • BEDARD EL, KIM P, JIANG J et al.: Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts. Transplantation (2003) 76(1):249-252.
  • LIU L, LALANI A, DAI E et al.: The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J. Clin. Invest. (2000) 105(11):1613-1621.
  • GRAHAM KA, LALANI AS, MACEN JL et al.: The T1/35 kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology (1997) 229(1):12-24.
  • POWER AT, BELL JC: Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol. Ther. (2007) 15(4):660-665.
  • POWER AT, WANG J, FALLS TJ et al.: Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. (2007) 15(1):123-130.
  • THORNE SH: Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors. Expert Opin. Biol. Ther. (2007) 7(1):41-51.
  • GILBERT P-A, MCFADDEN G: Poxvirus cancer therapy. Recent Patents Antiinfect. Drug Discov. (2006) 1:309-321.
  • MCKEE TD, GRANDI P, MOK W et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. (2006) 66(5):2509-2513.
  • GANESH S, GONZALEZ EDICK M, IDAMAKANTI N et al.: Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. (2007) 67(9):4399-4407.
  • KIM JH, LEE YS, KIM H et al.: Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. (2006) 98(20):1482-1493.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.